Abstract
Advocates who are highly motivated, active, and well educated about the disease landscape play a pivotal role in the success of drug development and approval. While qualitative and quantitative evidence of advocate impact in pediatric cancer drug development is sparse, the importance of advocate input is nevertheless championed by all stakeholders and is demonstrated by the growing publication rate on this subject.
The field of drug development for children with cancer has many challenges relating to scientific, ethical, logistical, economic, and regulatory issues. Driving progress in this acute disease area requires a multi-stakeholder approach. Putting unmet medical needs of patients first, early in the development process, can lead to focused priorities and better decisions on research design and potentially avoid costly late-stage failures.
To drive faster and increased access to innovative therapies, challenges and opportunities are discussed. Distinct efforts of research advocates to impact the research and drug development process and the impact of policy advocates on the legislative and regulatory environment are discussed. Recommendations are made to maximize opportunities for all stakeholders to attain their shared goal: evidence-based medicines reaching as many children and young people with cancer as possible.
Keywords
- Patient advocacy
- Drug development
- Patient engagement
- Patient-centered clinical trials
- Pediatric cancer
- Pediatric oncology
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
ACCELERATE (2021) ACCELERATE Educational Webinar on drug development in paediatric oncology (30 Mar)—Accelerate platform. Accelerate-platform.org [cited 2021 Jun 16]. Available from: https://www.accelerate-platform.org/2021/02/23/accelerate-educational-webinar/
Adamson P et al (2016) Translating discovery into cures for children with cancer. https://www.cancer.org/content/dam/cancer-org/research/translating-discovery-into-cures-for-children-with-cancer-landscape-report.pdf
Akhondzadeh S (2016) The importance of clinical trials in drug development. Avicenna J Med Biotechnol 8(4):151
Band of Parents (2021) Major Initiatives. Bandofparents.org [cited 2021 Jun 16]. Available from: https://www.bandofparents.org/our-impact/major-initiatives/
Bautista F, Di Giannatale A, Dias-Gastellier N, Fahd M, Valteau-Couanet D, Couanet D et al (2015) Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience: a 13-year center experience. J Pediatr Hematol Oncol 37(2):e102–e110
Bird N (2021) Dinutuximab: a newly approved immunotherapy for the treatment of neuroblastoma. Accelerate-platform.org [cited 2021 Jun 15]. Available from: https://www.accelerate-platform.org/wp-content/uploads/sites/4/2019/03/3.-Nick-Bird.pdf
C17 Council Blog (2021) The 100% Fund—C17 Council Blog. Wordpress.com [cited 2021 Jun 16]. Available from: https://c17blog.wordpress.com/category/the-100-fund/
Cardoen G (2020) Evaluation of the medicines for rare diseases and children legislation. Europa.eu [cited 2021 Jun 16]. Available from: https://ec.europa.eu/health/human-use/paediatric-medicines/evaluation_en
Center for Drug Evaluation, Research (2018) Advisory committees: critical to the FDA’s product review process. Fda.gov [cited 2021 Jun 16]. Available from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/advisory-committees-critical-fdas-product-review-process
Center for Drug Evaluation, Research (2021) FDA grants accelerated approval to naxitamab for high-risk neuroblasto. Fda.gov [cited 2021 Jun 16]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow
Crane S, Haase JE, Hickman SE (2018) Well-being of child and family participants in phase 1 pediatric oncology clinical trials. Oncol Nurs Forum 45(5):E67–E97
Crocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S et al (2018) Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ 363:k4738
Das S, Rousseau R, Adamson PC, Lo AW (2018) New business models to accelerate innovation in pediatric oncology therapeutics: a review. JAMA Oncol 4(9):1274–1280
Daue R (2017) The 2017 commission report on the paediatric regulation. Europa.eu [cited 2021 Jun 16]. Available from: https://ec.europa.eu/health/human-use/paediatric-medicines/developments/2016_pc_report_2017_en
Day One Biotherapeutics (2021) About—DayOne. Dayonebio.com [cited 2021 Jun 16]. Available from: https://dayonebio.com/about/
de Claro RA, Spillman D, Hotaki LT, Shum M, Mouawad LS, Santos GML et al (2020) Project Orbis: global collaborative review program. Clin Cancer Res 26(24):6412–6416
De Cock KM, Jaffe HW, Curran JW (2011) Reflections on 30 years of AIDS. Emerg Infect Dis 17(6):1044–1048
European Commission (2021) Medicines for children & rare diseases—updated rules. https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12767-Medicines-for-children-&-rare-diseases-updated-rules_en
European Medicines Agency (2021) Getting involved: patients, consumers and carers are involved in a wide range of European Medicines Agency (EMA) activities. Europa.eu [cited 2021 Jun 16]. Available from: https://www.ema.europa.eu/en/partners-networks/patients-consumers/getting-involved
European Parliament (2016) Texts adopted—Paediatric medicines—Thursday, 15 Dec 2016. Europa.eu [cited 2021 Jun 16]. Available from: https://www.europarl.europa.eu/doceo/document/TA-8-2016-0511_EN.html
FDA (2019) FDARA implementation guidance for pediatric studies of molecularly targeted oncology drugs: amendments to sec. 505B of the FD&C act guidance for industry. Fda.gov [cited 2021 Jun 15]. Available from: https://www.fda.gov/media/133440/download
GBD 2017 Childhood Cancer Collaborators (2019) The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol 20(9):1211–1225
Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M et al (2018) EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes. Front Med (Lausanne) 5:230
Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G et al (2015) Partnering with patients in the development and lifecycle of medicines: a call for action: a call for action. Ther Innov Regul Sci 49(6):929–939
Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR et al (2013) Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 309(22):2371–2381
Hunter A, Facey K, Thomas V, Haerry D, Warner K, Klingmann I et al (2018) EUPATI guidance for patient involvement in medicines research and development: health technology assessment. Front Med (Lausanne) 5:231
Kids V Cancer (2018) Priority Review Vouchers for rare pediatric diseases, issued and sold 2012–present. Kidsvcancer.org [cited 2021 Jun 15]. Available from: https://www.kidsvcancer.org/priority-review-vouchers/
Kids V Cancer (2021) Post-mortem tissue donation. Kidsvcancer.org [cited 2021 Jun 16]. Available from: https://www.kidsvcancer.org/tissue-donation/
Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC et al (2008) Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist 13(6):679–689
Klingmann I, Heckenberg A, Warner K, Haerry D, Hunter A, May M et al (2018) EUPATI and patients in medicines research and development: guidance for patient involvement in ethical review of clinical trials. Front Med (Lausanne) 5:251
Lowe MM, Blaser DA, Cone L, Arcona S, Ko J, Sasane R et al (2016) Increasing patient involvement in drug development. Value Health 19(6):869–878
Meyers DE, Jenei K, Chisamore TM, Gyawali B (2021) Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada. JAMA Intern Med 181(4):499–508
Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T et al (2014) Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience: the royal Marsden experience. J Pediatr Hematol Oncol 36(3):218–223
NBCC (2019) Project LEAD. Stopbreastcancer.org [cited 2021 Jun 16]. Available from: https://www.stopbreastcancer.org/what-we-do/education/project-lead/
Neel DV, Shulman DS, DuBois SG (2019) Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer 112:49–56
NICE (2015) National Institute for Health and Care Excellence single technology appraisal appeal hearing. Dinutuximab for treating high-risk neuroblastoma [ID799]. Org.uk [cited 2021 Jun 15]. Available from: https://www.nice.org.uk/guidance/gid-tag507/documents/appeal-decision
NICE (2018) Overview | Dinutuximab beta for treating neuroblastoma | Guidance | NICE [cited 2021 Jun 15]. Available from: https://www.nice.org.uk/guidance/ta538
Oncoheroes (2021) Founders—Oncoheroes Biosciences. Oncoheroes.com [cited 2021 Jun 16]. Available from: https://oncoheroes.com/founders
Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A et al (2019) ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. Eur J Cancer 110:74–85
Pearson ADJ, Karres D, Reaman G, DuBois SG, Knox L, Scobie N et al (2020a) The RACE to accelerate drug development for children with cancer. Lancet Child Adolesc Health 4(10):714–716
Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY et al (2020b) Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency. Eur J Cancer 136:116–129
Pearson AD, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers ML et al (2020c) Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer 139:135–148
Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J et al (2020d) ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer 127:52–66
Powell M (2018) Highlighting pediatric preclinical drug testing at the annual meeting 2018. Aacr.org [cited 2021 Jun 16]. Available from: https://www.aacr.org/blog/2018/04/12/highlighting-pediatric-preclinical-drug-testing-at-the-annual-meeting-2018/
Reaman GH (2018) Oncology Products. Relevant molecular targets for cancer drug development for children. Fda.gov [cited 2021 Jun 15]. Available from: https://www.fda.gov/media/128614/download
Richards DP, Jordan I, Strain K, Press Z (2018) Patient partner compensation in research and health care: the patient perspective on why and how. Patient Exp J 5(3):6–12
Richards DP, Birnie KA, Eubanks K, Lane T, Linkiewich D, Singer L et al (2020) Guidance on authorship with and acknowledgement of patient partners in patient-oriented research. Res Invol Engag 6(1):38
Rinde M (2021) Surge of new drugs fuels optimism in pediatric oncology. OncLive [cited 2021 Jun 15]. Available from: https://www.onclive.com/view/surge-of-new-drugs-fuels-optimism-in-pediatric-oncology
SIOPE (2016) European Childhood Cancer Organisations’ Recommendations following the European Commission’s evaluation of the legislation for medicines for rare diseases and children and the launch of the pharmaceutical strategy for Europe. Siope.eu [cited 2021 Jun 16]. Available from: https://siope.eu/media/documents/recommendations-for-paediatric-cancer-following-launch-of-the-pharmaceutical-strategy-for-europe.pdf
SIOPE (2019) European elections 2019 manifesto for childhood cancer. Siope.eu [cited 2021 Jun 16]. Available from: https://siope.eu/news/european-elections-2019-manifesto-paediatric-oncology-haematology-communit/
SIOPE (2021) Childhood cancer is under the spotlight in Europe’s Beating Cancer Plan :: SIOP Europe. Siope.eu [cited 2021 Jun 16]. Available from: https://siope.eu/news/childhood-cancer-under-spotlight-eu-cancer-plan/
Solving Kid’s Cancer (2021a) Landmark transatlantic trial for children with high-risk neuroblastoma funded by parent-led charities. Org.uk [cited 2021 Jun 16]. Available from: https://www.solvingkidscancer.org.uk/landmark-trans-atlantic-trial-for-children-with-high-risk-neuroblastoma
Solving Kid’s Cancer (2021b) PTPP—ITCC-P4 Collaboration. Org.uk [cited 2021 Jun 16]. Available from: https://www.solvingkidscancer.org.uk/ptpp-itcc-p4
The Boston Globe, Baker B (2021) The Power of Will. Bostonglobe.com [cited 2021 Jun 16]. Available from: https://apps.bostonglobe.com/metro/graphics/2016/12/will/?p1=Lacey_Short_URL
The Children’s Hospital of Philadelphia (2021) New treatment shows success in high-risk solid tumors. Chop.edu [cited 2021 Jun 16]. Available from: https://www.chop.edu/news/new-treatment-shows-success-high-risk-solid-tumors
Upton J (2019) Patient advocacy: the corporate mandate. PharmExec [cited 2021 Jun 16]. Available from: https://www.pharmexec.com/view/patient-advocacy-corporate-mandate
Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S et al (2015) Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur J Cancer 51(2):218–224
Vassal G, Houghton PJ, Pfister SM, Smith MA, Caron HN, Li X-N et al (2021) International consensus on minimum preclinical testing requirements for the development of innovative therapies for children and adolescents with cancer. Mol Cancer Ther 20:1462–1468
Warner K, See W, Haerry D, Klingmann I, Hunter A, May M (2018) EUPATI guidance for patient involvement in medicines research and development (R&D); guidance for pharmaceutical industry-led medicines R&D. Front Med (Lausanne) 5:270
WHO (2021) WHO launches new tools to help countries build effective childhood cancer programmes. Who.int [cited 2021 Jun 16]. Available from: https://www.who.int/news/item/15-02-2021-who-launches-new-tools-to-help-countries-build-effective-childhood-cancer-programmes
Y-mAbs Therapeutics (2019) Overview. Ymabs.com. [cited 2021 Jun 16]. Available from: https://ymabs.com/company/overview/
Acknowledgments
The authors gratefully acknowledge contributions and review by Elena Gerasimov of Kids V Cancer, Nick Bird of Solving Kids’ Cancer UK, Antonia Palmer of Kindred Foundation, Pia Rhiner and Kristi McKay of Solving Kids’ Cancer, and Garrett Robinson.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
This chapter is dedicated to the children and young people who participate in clinical research and their families. Their bravery and contribution to advancing research are recognized and valued.
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ludwinski, D., Scobie, N., Knox, L. (2022). Role of Patients and Advocates in Cancer Therapeutics Development. In: DiMartino, J., Reaman, G.H., Smith, F.O. (eds) Pediatric Cancer Therapeutics Development. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-06357-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-06357-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-06356-5
Online ISBN: 978-3-031-06357-2
eBook Packages: MedicineMedicine (R0)